Shkreli's former company beats Impax demand to block drug sales
May 18, 2016 at 18:27 PM EDT
NEW YORK, May 18 (Reuters) - Turing Pharmaceuticals does not have to recall thousands of bottles of a life-saving medicine that became the flashpoint of a pricing controversy after former Chief Executive Martin Shkreli raised its price by over 5,000 percent, a U.S. judge ruled on Wednesday.